Rezolute Inc (RZLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rezolute Inc (RZLT) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.73 Million) by net assets ($116.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Rezolute Inc worth for the company's overall valuation and market capitalisation.
Rezolute Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rezolute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rezolute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rezolute Inc ranked by their cash flow conversion efficiency. See Rezolute Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Newamstar Packaging Machinery Co Ltd
SHE:300509
|
0.212x |
|
Pes Camanchaca
SN:CAMANCHACA
|
0.052x |
|
PGIM Short Duration High Yield Opportunities Fund
NYSE:SDHY
|
N/A |
|
Barnes & Noble Education Inc
NYSE:BNED
|
0.274x |
|
Tianjin Motimo Membrane Tech
SHE:300334
|
-0.028x |
|
Shenzhen Tongyi Industry Co Ltd
SHE:300538
|
-0.017x |
|
Fondul Proprietatea SA
RO:FP
|
N/A |
|
International Money Express Inc
NASDAQ:IMXI
|
-0.123x |
Annual Cash Flow Conversion Efficiency for Rezolute Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rezolute Inc from 2012 to 2025. View Rezolute Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $162.13 Million | $-69.08 Million | -0.426x | +10.13% |
| 2024-06-30 | $121.00 Million | $-57.37 Million | -0.474x | -23.82% |
| 2023-06-30 | $116.17 Million | $-44.48 Million | -0.383x | -44.46% |
| 2022-06-30 | $149.47 Million | $-39.62 Million | -0.265x | +66.16% |
| 2021-06-30 | $26.10 Million | $-20.44 Million | -0.783x | +76.13% |
| 2020-06-30 | $7.37 Million | $-24.17 Million | -3.281x | +62.43% |
| 2019-06-30 | $1.75 Million | $-15.30 Million | -8.735x | -345.15% |
| 2018-06-30 | $-3.96 Million | $-14.11 Million | 3.563x | +328.28% |
| 2017-06-30 | $8.53 Million | $-13.31 Million | -1.561x | -30.56% |
| 2016-06-30 | $8.77 Million | $-10.49 Million | -1.196x | -52.91% |
| 2015-06-30 | $9.05 Million | $-7.08 Million | -0.782x | -58.15% |
| 2014-06-30 | $6.41 Million | $-3.17 Million | -0.494x | -226.40% |
| 2013-06-30 | $-4.16 Million | $-1.63 Million | 0.391x | +1147.91% |
| 2012-06-30 | $-1.29 Million | $-40.40K | 0.031x | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more